Loading
CalciMedica, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Middleton Fred A, was filed 29 Jun 2026.
Insider Decl.
226
Thresholds
n/a
Buy Volume
€39M
118 ops. · all time
Sell Volume
€27,696
3 ops. · all time
Who traded when
BuySaleEric W. Roberts20 buys
A. Rachel Leheny3 buys
Fred A. Middleton3 buys
Kenneth A. Stauderman2 buys1 sale
Sudarshan Hebbar3 buys
Robert N. Wilson2 buys
+2 other insiders
Since the insiders bought
- -77.7%Entry US$5.15 · Close 22 Oct 2026 US$1.15
- -88.6%Entry US$15.65 · Close at T+365 US$1.79
- -80.0%Entry US$13.90 · Close at T+365 US$2.78
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate CalciMedica, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$38.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.15
Analyst consensus
3 analystsStrong buy
US$9.00Target US$38.00(+3204%)US$75.00
Income statement
EBITDA-US$28.1M
Net income-US$29.6M0.0% margin
Valuation
P/Book1.3x
Beta1.10
Balance sheet & cash
Market capUS$7.9M
Total debtUS$9.7M
Free Cash Flow-US$21.2M
Debt / Equity167%
Profitability & ownership
ROE-365.7%
ROA-63.6%
% insiders18.5%
% institutions57.5%
Last declaration on 29 June 2026
Declarations226 total
248,972 shares@ US$0.8033100.0% of flowCommon StockSEC:0001267959-26-000003:0
Canonical exit: 23 Sept 2026 (T+90)
1,182,621 sharesCommon StockSEC:0001189022-26-000002:0
186,729 sharesCommon StockSEC:0001484729-26-000004:0
186,729 sharesCommon StockSEC:0001576244-26-000004:0
124,486 sharesCommon StockSEC:0001968793-26-000004:0
2,500 shares@ US$3.070.8% of flowCommon StockSEC:0001576244-25-000007:0
Canonical exit: 17 Dec 2025 (T+90)
3,400 shares@ US$2.67790.9% of flowCommon StockSEC:0001576244-25-000005:0
Canonical exit: 14 Dec 2025 (T+90)
5,000 shares@ US$3.121.6% of flowCommon StockSEC:0001576244-25-000003:0
Canonical exit: 11 Dec 2025 (T+90)
2,343 shares@ US$3.14880.8% of flowCommon StockSEC:0001415889-25-024256:0
Canonical exit: 8 Dec 2025 (T+90)
800 shares@ US$2.740.2% of flowCommon StockSEC:0001415889-25-023364:1
Canonical exit: 27 Nov 2025 (T+90)
9,200 shares@ US$2.8632.8% of flowCommon StockSEC:0001415889-25-023364:0
Canonical exit: 26 Nov 2025 (T+90)
3,508 shares@ US$2.79281.0% of flowCommon StockSEC:0001415889-25-022850:0
Canonical exit: 19 Nov 2025 (T+90)
2,000 shares@ US$2.720.5% of flowCommon StockSEC:0001415889-25-022550:1
Canonical exit: 18 Nov 2025 (T+90)
15,000 shares@ US$1.532.0% of flowCommon StockSEC:0001415889-25-022550:2
1,000 shares@ US$2.790.3% of flowCommon StockSEC:0001415889-25-022550:0
Canonical exit: 17 Nov 2025 (T+90)
9,563 shares@ US$2.819416.0% of flowCommon StockSEC:0001415889-25-022549:0
Canonical exit: 17 Nov 2025 (T+90)
5,076 shares@ US$2.89771.5% of flowCommon StockSEC:0001415889-25-022261:0
Canonical exit: 13 Nov 2025 (T+90)
4,392 shares@ US$2.796.8% of flowCommon StockSEC:0001415889-25-022159:1
Canonical exit: 13 Nov 2025 (T+90)
1,584 shares@ US$2.5852.4% of flowCommon StockSEC:0001415889-25-022159:0
Canonical exit: 12 Nov 2025 (T+90)
1,000 shares@ US$3.9642.2% of flowCommon StockSEC:0001415889-25-020458:1
Canonical exit: 26 Oct 2025 (T+90)
1,000 shares@ US$3.6566.5% of flowCommon StockSEC:0001415889-25-020458:0
1,500 shares@ US$3.7750.6% of flowCommon StockSEC:0001415889-25-020164:0
Canonical exit: 20 Oct 2025 (T+90)
1,500 shares@ US$3.370.5% of flowCommon StockSEC:0001415889-25-020111:0
Canonical exit: 19 Oct 2025 (T+90)
1,000 shares@ US$3.400.6% of flowCommon StockSEC:0001415889-25-020052:0
Canonical exit: 19 Oct 2025 (T+90)
4,500 shares@ US$2.871.3% of flowCommon StockSEC:0001415889-25-019998:0
Canonical exit: 16 Oct 2025 (T+90)
25 of 226 declarations
About CalciMedica, Inc.
On September 29, 2020, Clarus Lifesciences III, L.P., 10% Owner of CalciMedica, Inc., bought for EUR 3,406,560, the largest purchase on file; Sanderling Venture Partners VI LP follows with EUR 828,021 and EUR 661,693 on January 23, 2024. In all, 120 purchases, 118 of them with an amount, are worth EUR 9.8 million (median EUR 7,261), against 3 sales worth EUR 27,696: 98% of open-market trades are purchases, and 105 purchase filings fall in 30-day windows. Eric W. Roberts, Chief Business Officer, signs 58 of the 225 filings, 51 of them purchases. Fred A. Middleton, Director, has 25 including 15 purchases, A. Rachel Leheny, Chief Executive Officer, 22 including 17. The sales are small: Robert S. Breuil, Chief Financial Officer, EUR 22,121 on September 22, 2021 and EUR 2,470 on March 31, 2022, Kenneth A. Stauderman, Chief Scientific Officer, EUR 3,105 on July 25, 2025. From July 18 to August 15, 2025, 5 insiders bought for EUR 58,201. Filings from 24 filers were published from September 29, 2020 to June 29, 2026, peaking at 104 in 2023, with 59 grants. In the last twelve months, 5 filings include 1 purchase. The US health care company is worth USD 7.9 million, with 18.5% held by insiders. For 95 purchases the stored 90-day result has a median of --5%, with 38% of results positive: recorded past results, not a forecast.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
